Current therapy of chronic myelogenous leukemia

Internal Medicine

Volumn 41, Issue 4, 2002, Pages 254-264

  Garcia Manero, Guillermo ^a   Talpaz, Moshe ^a   Kantarjian, Hagop M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Decitabine; Homoharring tonine; Imatinib mesylate; Interferon; Transplant

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALPHA INTERFERON; BCR ABL PROTEIN; BUSULFAN; CYTARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; HOMOHARRINGTONINE; HYDROXYUREA; IMATINIB; MACROGOL; PEGINTERFERON ALPHA2A; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; TIPIFARNIB;

ADULT; AGE; ARTHRALGIA; BONE MARROW SUPPRESSION; BONE PAIN; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG ACTIVITY; ENZYME ACTIVATION; FEMALE; FLUID RETENTION; GASTROINTESTINAL DISEASE; GENETIC CODE; HEMATOLOGIC DISEASE; HUMAN; MALE; MALIGNANT TRANSFORMATION; MEDICAL DECISION MAKING; MUSCLE CRAMP; MYELOPROLIFERATIVE DISORDER; NAUSEA AND VOMITING; PROGNOSIS; RASH; REVIEW; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; WEIGHT GAIN;

EID: 0036245352     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.41.254     Document Type: Review

References (81)

1. The biology of chronic myeloid leukemia
2. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein
3. Treatment of myelogenous leukemia: Current status and investigational options
4. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22
5. A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia
6. Neutrophilic-chronic myeloid leukemia: A distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction)
7. Chronic myelogenous leukemia: A concise update
8. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals
9. Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period
10. Characteristics of accelerated disease in chronic myelogenous leukemia
11. Chronic myelogenous leukemia in the lymphoid blastic phase: Characteristics, treatment response, and prognosis
12. Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia
13. Prognostic discrimination in chronic granulocytic leukemia
14. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa
15. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service
16. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia
17. Prognosis of patients with CML: Updated results of the collaborative CML prognostic factors project
18. Large deletions at the t(9; 22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia
19. Molecular follow-up of disease progression and interferon therapy in chronic myelocytic leukemia
20. Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry
21. Treatment of chronic myelogenous leukemia with allogeneic bone marrow transplantation after preparation with busulfan and cyclophosphamide (BuCy2): An update
22. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: Prolongation of survival by hydroxyurea
23. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology
24. Bone marrow transplantation for chronic myeloid leukemia: Long-term results
25. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase
26. Allografting for chronic myeloid leukaemia
27. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: A report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
28. Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia
29. Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome
30. Survival after allogeneic bone marrow transplantation in patients randomized into a trial of IFN alpha versus chemotherapy: No significant adverse effect of prolonged IFN alpha administration
31. Absence of influence of prior treatment with interferon on the outcome of allogeneic bone marrow transplantation for chronic myeloid leukemia
32. The adverse influence of pretransplant interferon-alpha (IFN-alpha) on transplant outcome after marrow transplantation for chronic phrase chronic myelogenous leukemia increases with the duration of IFN-alpha exposure
33. Prior treatment with alpha interferon does not adversely affect the outcome of allogeneic transplantation for CML
34. Prior treatment with alpha-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia
35. Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure
36. Therapeutic choices in younger patients with chronic myelogenous leukemia
37. Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase
38. Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia: An analysis from the international bone marrow transplant registry
39. Effect of interferon-alpha (IFN) on outcome of unrelated donor (URD) bone marrow transplantation (BMT)
40. Regimen-related toxicity of a busulfan-cyclophosphamide conditionining regimen in 70 patients undergoing allogeneic bone marrow transplantation
41. Graft-versus-leukemia reactions after bone marrow transplantation
42. Donor lymphocyte infusions
43. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program
44. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia
45. Favorable outcome of non-myeloablative stem cell transplant (NMSCT) for chronic myeloid leukemia (CML) in first chronic phase: A retrospective study of the European Group for Blood and Marrow Transplantation (EBMT)
46. Interferon alfa versus chemotherapy for chronic myeloid leukemia: A meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group
47. Evidence for a selective antileukemic effect of cytosine arabinoside in chronic granulocytic leukemia
48. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine
49. Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: Results of the Austrian multicenter phase II study
50. Combined interferon and low-dose cytosine arabinoside for Ph+chronic phase myeloid leukemia
51. Combined interferon alpha-2a and cytosine arabinoside as first-line treatment for chronic myeloid leukemia
52. Cytarabine increases karyotypic response in IFNα treated chronic myeloid leukemia patients: Results of a national prospective randomized trial of the Italian Cooperative Study Group on CML
53. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148)
54. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
55. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins
56. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
57. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
58. Phase II study of STI571, a tyrosine kinase inhibitor, in patients (pts) with resistant or refractory Philadelphia chromosome-positive chronic myeloid leukemia (Ph+CML)
59. A phase II study of STI571 in adult patients with Philadelphia chromosome positive chronic myelogenous leukemia in accelerated phase
60. A phase II study to determine the safety and anti-leukemic effects of STI571 in patients with Philadelphia chromosome positive chronic myeloid leukemia in myeloid blast crisis
61. The hyper-CVAD regimen in adult acute lymphocytic leukemia
62. Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia
63. PEG-interferon a-2A (PEGASYS™) with or without cytarabine in patients with relapsed or refractory chronic phase CML
64. A phase II study of interferon alpha (IFN) and intermittent oral cytarabine (YNK01) in the treatment of newly diagnosed chronic myeloid leukemia (CML)
65. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase
66. Homoharringtonine and low-dose cytosine arabinoside (LDara-C) in late chronic phase chronic myelogenous leukemia
67. A new series of homoharringtonine (HHT) analogs exhibiting a potent antileukemic activity in vitro
68. DNA methylation changes in hematologic malignancies: Biologic and clinical implications
69. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia
70. GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia
71. GM-CSF and interferon (INF) rapidly induce cytogenetic remissions in chronic myeloid leukemia (CML)
72. Targeting the Ras signaling pathway: A rational, mechanism-based treatment for hematologic malignancies?
73. Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336
74. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia
75. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase 1 clinical-laboratory correlative trial
76. Randomized comparison of allogeneic bone marrow transplantation and IFN based drug treatment in CML
77. Fractionated total-body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phase
78. Marrow transplantation for chronic myeloid leukemia: A randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide
79. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: A randomized trial of two irradiation regimens
80. Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2
81. 1993 progress report from the International Bone Marrow Transplant Registry. Advisory Committee of the International Bone Marrow Transplant Registry